Furthermore, CXCR6+ CD8+ T cells have been characterized as more immunocompetent compared to their CXCR6− counterparts, further supporting the potential of targeting this axis to enhance immune responses in cancer immunotherapy [64]. This evidence concerns the gene CXCR6 and cancer.